Table 1.
Efficacy of dapagliflozin in various studies
| Study | Dapagliflozin dose | Placebo-corrected decrease in HbA1c (%) | Placebo-corrected achievement of goal HbA1c < 7% (%) | Placebo-corrected decrease in FPG (mmol/L) | Placebo-corrected decrease in PPBG (mmol/L) | Placebo-corrected weight reduction (kg) |
|---|---|---|---|---|---|---|
| Bailey et al | 2.5, 5, 10 mg | 0.37–0.54 | 7.1–14.7 | 0.66–0.97 | N/A | 1.3–2.0 |
| Bolinder et al | 10 mg | 0.28 | N/A | 0.95 | N/A | 2.08 |
| Ferranini et al | 2.5, 5, 10 mg | 0.35–0.66 | 9–19 | 0.62–1.37 | N/A | 0.6–1.1 |
| List et al | 2.5, 5, 10, 20, 50 mg | 0.37–0.72 | 8–27 | 0.55–1.39 | 1.19–2.15 | 1.3–2.2 |
| Nauck et al* | 10 and 20 mg | 0 | 4.6 | 0.20 | N/A | 4.65 |
| Strojek et al | 2.5, 5, 10 mg | 0.45–0.69 | 17.3–18.7 | 1.07–1.47 | 1.45–1.61 | 0.46–1.54 |
| Wilding et al | 10 and 20 mg | 0.70–0.78 | N/A | 0.85–1.52 | 2.94–3.36 | 2.4–2.6 |
| Zhang et al+ | 10 and 20 mg | E, 0.3–0.5 | N/A | N/A | N/A | E, 1.05–1.55 |
| L, 0.6–0.8 | L, 2.75–3.5 |
Notes:
*
Dapagliflozin was compared with glipizide, not placebo, in a noninferiority trial;
+
patients with type 2 diabetes divided into early and late stages.
Abbreviations: E, early, L, late; N/A, not available; FPG, fasting plasma glucose.